 Kelly Knupp
Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticonvulsants | 35 | 2025 | 222 | 7.420 |
Why?
| | Spasms, Infantile | 26 | 2025 | 133 | 7.350 |
Why?
| | Epilepsies, Myoclonic | 31 | 2025 | 57 | 7.090 |
Why?
| | Lennox Gastaut Syndrome | 8 | 2025 | 19 | 4.370 |
Why?
| | Epilepsy | 19 | 2025 | 359 | 3.360 |
Why?
| | Seizures | 28 | 2025 | 441 | 2.770 |
Why?
| | Vigabatrin | 10 | 2025 | 19 | 2.750 |
Why?
| | Adrenocorticotropic Hormone | 8 | 2025 | 147 | 2.560 |
Why?
| | Fenfluramine | 10 | 2025 | 17 | 2.200 |
Why?
| | Electroencephalography | 12 | 2024 | 522 | 1.660 |
Why?
| | Drug Resistant Epilepsy | 8 | 2025 | 105 | 1.550 |
Why?
| | Epilepsies, Partial | 5 | 2025 | 57 | 1.520 |
Why?
| | Epilepsy, Generalized | 3 | 2023 | 19 | 1.110 |
Why?
| | Glucocorticoids | 3 | 2020 | 534 | 1.030 |
Why?
| | Caregivers | 7 | 2025 | 940 | 1.030 |
Why?
| | Delphi Technique | 3 | 2024 | 314 | 0.970 |
Why?
| | Developmental Disabilities | 5 | 2025 | 288 | 0.960 |
Why?
| | Infant | 34 | 2025 | 9820 | 0.900 |
Why?
| | Prednisolone | 5 | 2025 | 68 | 0.890 |
Why?
| | Plant Extracts | 4 | 2020 | 209 | 0.880 |
Why?
| | NAV1.6 Voltage-Gated Sodium Channel | 1 | 2024 | 11 | 0.860 |
Why?
| | Cannabidiol | 4 | 2022 | 126 | 0.860 |
Why?
| | Child, Preschool | 32 | 2025 | 11511 | 0.830 |
Why?
| | Child | 48 | 2025 | 22390 | 0.790 |
Why?
| | Status Epilepticus | 5 | 2024 | 54 | 0.780 |
Why?
| | Genetic Therapy | 2 | 2023 | 315 | 0.770 |
Why?
| | Humans | 89 | 2025 | 141284 | 0.690 |
Why?
| | Medical Marijuana | 2 | 2019 | 124 | 0.660 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 6 | 2025 | 21 | 0.650 |
Why?
| | Dioxolanes | 2 | 2020 | 6 | 0.650 |
Why?
| | Sleep | 4 | 2024 | 882 | 0.640 |
Why?
| | Treatment Outcome | 20 | 2025 | 11216 | 0.600 |
Why?
| | Adolescent | 29 | 2025 | 22116 | 0.540 |
Why?
| | Leukomalacia, Periventricular | 1 | 2017 | 9 | 0.540 |
Why?
| | Male | 51 | 2025 | 70140 | 0.530 |
Why?
| | Thyrotropin | 1 | 2017 | 116 | 0.520 |
Why?
| | Precision Medicine | 1 | 2021 | 435 | 0.520 |
Why?
| | Female | 51 | 2025 | 75814 | 0.490 |
Why?
| | Infant, Premature, Diseases | 1 | 2017 | 108 | 0.480 |
Why?
| | Disease Progression | 4 | 2025 | 2808 | 0.470 |
Why?
| | Cannabis | 3 | 2020 | 510 | 0.460 |
Why?
| | Treatment Failure | 1 | 2016 | 355 | 0.460 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 314 | 0.450 |
Why?
| | Executive Function | 3 | 2025 | 459 | 0.450 |
Why?
| | Perception | 1 | 2017 | 375 | 0.420 |
Why?
| | Lafora Disease | 1 | 2014 | 1 | 0.420 |
Why?
| | Unverricht-Lundborg Syndrome | 1 | 2014 | 1 | 0.420 |
Why?
| | Testosterone | 1 | 2017 | 404 | 0.410 |
Why?
| | Migraine Disorders | 2 | 2024 | 106 | 0.410 |
Why?
| | Epilepsy, Absence | 2 | 2023 | 9 | 0.400 |
Why?
| | Myoclonus | 2 | 2023 | 15 | 0.400 |
Why?
| | Administration, Oral | 5 | 2019 | 825 | 0.400 |
Why?
| | Prospective Studies | 14 | 2025 | 7805 | 0.400 |
Why?
| | Physicians | 1 | 2021 | 930 | 0.390 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1546 | 0.390 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 501 | 0.380 |
Why?
| | Epileptic Syndromes | 5 | 2024 | 92 | 0.350 |
Why?
| | Cost of Illness | 3 | 2018 | 311 | 0.340 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 374 | 0.340 |
Why?
| | Coronavirus Infections | 3 | 2020 | 370 | 0.340 |
Why?
| | Hypertension | 1 | 2019 | 1250 | 0.340 |
Why?
| | Parents | 3 | 2022 | 1439 | 0.320 |
Why?
| | Retrospective Studies | 14 | 2025 | 16447 | 0.320 |
Why?
| | Pandemics | 4 | 2022 | 1655 | 0.290 |
Why?
| | Dronabinol | 3 | 2022 | 240 | 0.290 |
Why?
| | Cognition | 3 | 2025 | 1226 | 0.280 |
Why?
| | Quality of Life | 5 | 2025 | 3024 | 0.280 |
Why?
| | Young Adult | 10 | 2025 | 13727 | 0.280 |
Why?
| | Neuropsychological Tests | 4 | 2025 | 1090 | 0.280 |
Why?
| | Cohort Studies | 8 | 2025 | 5809 | 0.280 |
Why?
| | Cannabinoids | 2 | 2022 | 178 | 0.270 |
Why?
| | Genetic Testing | 2 | 2023 | 462 | 0.270 |
Why?
| | Consensus | 3 | 2024 | 538 | 0.270 |
Why?
| | Biological Ontologies | 1 | 2025 | 20 | 0.230 |
Why?
| | Headache | 1 | 2006 | 153 | 0.230 |
Why?
| | Diet, Ketogenic | 1 | 2025 | 36 | 0.220 |
Why?
| | Seizures, Febrile | 1 | 2024 | 22 | 0.220 |
Why?
| | Double-Blind Method | 4 | 2023 | 1992 | 0.220 |
Why?
| | Dichloroacetic Acid | 1 | 2024 | 8 | 0.220 |
Why?
| | Adult | 13 | 2025 | 39319 | 0.220 |
Why?
| | Vagus Nerve Stimulation | 1 | 2024 | 28 | 0.220 |
Why?
| | Delivery of Health Care | 3 | 2020 | 948 | 0.220 |
Why?
| | Acidosis, Lactic | 1 | 2024 | 46 | 0.210 |
Why?
| | Analgesics | 1 | 2006 | 231 | 0.210 |
Why?
| | Natural Language Processing | 1 | 2025 | 103 | 0.200 |
Why?
| | Epilepsy, Reflex | 1 | 2023 | 1 | 0.200 |
Why?
| | Comorbidity | 2 | 2019 | 1671 | 0.200 |
Why?
| | Betacoronavirus | 3 | 2020 | 277 | 0.200 |
Why?
| | Video Recording | 1 | 2024 | 197 | 0.190 |
Why?
| | Family | 2 | 2018 | 677 | 0.190 |
Why?
| | Lymphocytes | 1 | 2025 | 390 | 0.190 |
Why?
| | Wakefulness | 1 | 2024 | 170 | 0.190 |
Why?
| | Spasm | 1 | 2022 | 21 | 0.180 |
Why?
| | Cosyntropin | 1 | 2022 | 7 | 0.180 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 25 | 0.180 |
Why?
| | Benzazepines | 2 | 2018 | 35 | 0.180 |
Why?
| | Outpatients | 1 | 2025 | 425 | 0.170 |
Why?
| | Delayed Diagnosis | 1 | 2021 | 91 | 0.170 |
Why?
| | Oligonucleotides, Antisense | 1 | 2021 | 110 | 0.170 |
Why?
| | Dependovirus | 1 | 2021 | 76 | 0.170 |
Why?
| | Shab Potassium Channels | 1 | 2020 | 18 | 0.170 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2020 | 15 | 0.160 |
Why?
| | Standard of Care | 1 | 2020 | 77 | 0.160 |
Why?
| | Infant, Newborn | 7 | 2024 | 6270 | 0.150 |
Why?
| | Internationality | 1 | 2020 | 156 | 0.150 |
Why?
| | Machine Learning | 1 | 2025 | 555 | 0.150 |
Why?
| | Causality | 1 | 2019 | 131 | 0.150 |
Why?
| | Hormones | 1 | 2019 | 138 | 0.150 |
Why?
| | Eyelids | 3 | 2023 | 42 | 0.150 |
Why?
| | Mutation | 3 | 2023 | 4006 | 0.140 |
Why?
| | Drug Approval | 1 | 2019 | 87 | 0.140 |
Why?
| | Health Surveys | 2 | 2018 | 511 | 0.140 |
Why?
| | Tandem Mass Spectrometry | 2 | 2022 | 565 | 0.140 |
Why?
| | Mitochondria | 1 | 2025 | 962 | 0.140 |
Why?
| | Health Care Surveys | 1 | 2020 | 561 | 0.140 |
Why?
| | Phenobarbital | 1 | 2018 | 19 | 0.140 |
Why?
| | Sickness Impact Profile | 1 | 2018 | 58 | 0.140 |
Why?
| | Animals | 6 | 2021 | 37328 | 0.140 |
Why?
| | Incidence | 2 | 2019 | 2809 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2025 | 5222 | 0.130 |
Why?
| | Urine | 1 | 2017 | 62 | 0.130 |
Why?
| | United States | 7 | 2019 | 15298 | 0.130 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein U | 1 | 2017 | 7 | 0.130 |
Why?
| | Body Height | 1 | 2017 | 200 | 0.120 |
Why?
| | Brain | 3 | 2018 | 2857 | 0.120 |
Why?
| | Heterozygote | 1 | 2017 | 306 | 0.120 |
Why?
| | Employment | 1 | 2018 | 180 | 0.120 |
Why?
| | Neuroimaging | 1 | 2018 | 278 | 0.120 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 5948 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 222 | 0.120 |
Why?
| | Benzimidazoles | 1 | 2017 | 191 | 0.120 |
Why?
| | Intellectual Disability | 1 | 2017 | 174 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1243 | 0.110 |
Why?
| | Serotonin | 1 | 2017 | 289 | 0.110 |
Why?
| | Neurology | 3 | 2020 | 112 | 0.110 |
Why?
| | Telemedicine | 2 | 2020 | 893 | 0.110 |
Why?
| | Health Care Costs | 1 | 2018 | 417 | 0.110 |
Why?
| | Nervous System Diseases | 1 | 2017 | 278 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 910 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2018 | 560 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2015 | 199 | 0.100 |
Why?
| | Body Weight | 1 | 2017 | 992 | 0.100 |
Why?
| | Infant, Premature | 1 | 2017 | 599 | 0.090 |
Why?
| | Colorado | 2 | 2019 | 4599 | 0.090 |
Why?
| | Pentobarbital | 1 | 2011 | 17 | 0.090 |
Why?
| | Age of Onset | 3 | 2018 | 536 | 0.090 |
Why?
| | Communication | 3 | 2024 | 941 | 0.090 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 124 | 0.090 |
Why?
| | Mental Health | 1 | 2018 | 756 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 874 | 0.080 |
Why?
| | Neurologists | 2 | 2021 | 22 | 0.080 |
Why?
| | Research Design | 1 | 2017 | 1105 | 0.080 |
Why?
| | Piracetam | 1 | 2010 | 12 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 684 | 0.080 |
Why?
| | Limit of Detection | 2 | 2022 | 94 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 2210 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2011 | 215 | 0.080 |
Why?
| | Middle Aged | 7 | 2025 | 34658 | 0.070 |
Why?
| | Forecasting | 2 | 2024 | 383 | 0.070 |
Why?
| | Prevalence | 1 | 2016 | 2795 | 0.070 |
Why?
| | Health Resources | 2 | 2020 | 126 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1043 | 0.060 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2005 | 61 | 0.060 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2025 | 74 | 0.060 |
Why?
| | Maternal Behavior | 1 | 2005 | 80 | 0.060 |
Why?
| | Pyruvate Dehydrogenase (Lipoamide) | 1 | 2024 | 10 | 0.060 |
Why?
| | Cell Respiration | 1 | 2025 | 106 | 0.060 |
Why?
| | Oxytocin | 1 | 2005 | 51 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1505 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2006 | 1491 | 0.050 |
Why?
| | Disease Management | 2 | 2020 | 634 | 0.050 |
Why?
| | Rare Diseases | 1 | 2025 | 111 | 0.050 |
Why?
| | Heredodegenerative Disorders, Nervous System | 1 | 2004 | 3 | 0.050 |
Why?
| | Hyalin | 1 | 2004 | 4 | 0.050 |
Why?
| | Intranuclear Inclusion Bodies | 1 | 2004 | 5 | 0.050 |
Why?
| | Wechsler Scales | 1 | 2024 | 55 | 0.050 |
Why?
| | Syncope | 1 | 2024 | 58 | 0.050 |
Why?
| | Aggression | 1 | 2005 | 194 | 0.050 |
Why?
| | Introns | 1 | 2024 | 253 | 0.050 |
Why?
| | Signal Transduction | 1 | 2017 | 5116 | 0.050 |
Why?
| | Phenotype | 2 | 2025 | 3172 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2025 | 337 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2015 | 2831 | 0.050 |
Why?
| | Rectum | 1 | 2004 | 187 | 0.050 |
Why?
| | Fatty Acids | 1 | 2025 | 446 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2025 | 712 | 0.040 |
Why?
| | Pediatrics | 2 | 2020 | 1102 | 0.040 |
Why?
| | Risk Factors | 1 | 2016 | 10490 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2020 | 3734 | 0.040 |
Why?
| | Eosinophils | 1 | 2004 | 319 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2024 | 839 | 0.040 |
Why?
| | Inpatients | 1 | 2025 | 513 | 0.040 |
Why?
| | Health Services | 1 | 2021 | 116 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 452 | 0.040 |
Why?
| | Videoconferencing | 1 | 2020 | 66 | 0.040 |
Why?
| | Tuberous Sclerosis | 1 | 2020 | 55 | 0.040 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 680 | 0.040 |
Why?
| | Internet | 1 | 2024 | 683 | 0.040 |
Why?
| | Placebos | 1 | 2019 | 195 | 0.040 |
Why?
| | Cell Line | 1 | 2025 | 2863 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1820 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 115 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 145 | 0.040 |
Why?
| | Biological Availability | 1 | 2019 | 137 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2025 | 926 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2020 | 5653 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 131 | 0.040 |
Why?
| | Drug Resistance | 1 | 2019 | 149 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 325 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2004 | 630 | 0.040 |
Why?
| | Critical Illness | 1 | 2024 | 852 | 0.030 |
Why?
| | Gene Ontology | 1 | 2018 | 51 | 0.030 |
Why?
| | Neurologic Examination | 2 | 2011 | 127 | 0.030 |
Why?
| | Preexisting Condition Coverage | 1 | 2017 | 3 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2929 | 0.030 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 26 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1137 | 0.030 |
Why?
| | Waiting Lists | 1 | 2019 | 245 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1519 | 0.030 |
Why?
| | Agenesis of Corpus Callosum | 1 | 2017 | 13 | 0.030 |
Why?
| | Efficiency | 1 | 2018 | 101 | 0.030 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2017 | 22 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 384 | 0.030 |
Why?
| | Muscle Hypotonia | 1 | 2017 | 33 | 0.030 |
Why?
| | Medicaid | 1 | 2021 | 450 | 0.030 |
Why?
| | Receptors, Serotonin | 1 | 2017 | 34 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2017 | 75 | 0.030 |
Why?
| | Chromosome Deletion | 1 | 2017 | 118 | 0.030 |
Why?
| | Income | 1 | 2018 | 198 | 0.030 |
Why?
| | Drug Costs | 1 | 2018 | 114 | 0.030 |
Why?
| | Microcephaly | 1 | 2017 | 101 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2017 | 242 | 0.030 |
Why?
| | Larva | 1 | 2017 | 237 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2018 | 267 | 0.030 |
Why?
| | RNA Splicing | 1 | 2017 | 271 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 589 | 0.030 |
Why?
| | Central Nervous System | 1 | 2017 | 264 | 0.030 |
Why?
| | Gestational Age | 1 | 2018 | 952 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 309 | 0.030 |
Why?
| | Vaccination | 1 | 2022 | 1468 | 0.020 |
Why?
| | Zebrafish | 1 | 2017 | 503 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 873 | 0.020 |
Why?
| | Genetic Variation | 1 | 2017 | 993 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2055 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 418 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2233 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4080 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 202 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 771 | 0.020 |
Why?
| | Kidney | 1 | 2017 | 1482 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2366 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1490 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 3007 | 0.020 |
Why?
| | Hospitalization | 1 | 2018 | 2264 | 0.020 |
Why?
| | Acute Disease | 1 | 2010 | 1005 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4414 | 0.020 |
Why?
| | Nalidixic Acid | 1 | 2005 | 1 | 0.010 |
Why?
| | Naphthyridines | 1 | 2005 | 19 | 0.010 |
Why?
| | Fluoxetine | 1 | 2005 | 56 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2765 | 0.010 |
Why?
| | Drug Synergism | 1 | 2005 | 367 | 0.010 |
Why?
| | Submucous Plexus | 1 | 2004 | 2 | 0.010 |
Why?
| | Myenteric Plexus | 1 | 2004 | 4 | 0.010 |
Why?
| | Consanguinity | 1 | 2004 | 49 | 0.010 |
Why?
| | Aged | 1 | 2022 | 24836 | 0.010 |
Why?
| | Postpartum Period | 1 | 2005 | 345 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2005 | 513 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2047 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1073 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2511 | 0.010 |
Why?
| | Ultrasonography | 1 | 2004 | 765 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 6951 | 0.010 |
Why?
| | Rats | 1 | 2005 | 5556 | 0.010 |
Why?
| | Neurons | 1 | 2004 | 1611 | 0.010 |
Why?
| | Pregnancy | 1 | 2005 | 7035 | 0.010 |
Why?
|
|
Knupp's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|